Navigation Links
Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
Date:11/14/2012

trials it will be sufficient for registration as a chronic use therapy and an IND is being prepared.
  • Multiple sites for the conduct of the trials have been identified and several CRO proposals were received and are being evaluated.
  • Ampio has an extensive portfolio of patents for Ampion™ and expects additional patents to be awarded, worldwide that encompass composition of matter, uses and synthesis patents.
  • Optina™

    Optina™ is an orally administered ultra-low dose of danazol for the treatment of diabetic macular edema (DME).

    • A phase 2a clinical trial conducted in Canada demonstrated encouraging results.
    • Scientific, peer-reviewed manuscripts, on the mechanism of action of the Optina™ were recently published in BBRC (Biochem Biophys Res Commun. 2012 May 18;421(4):707-12) and as a cover story was published in Retina Today (October 2012 issue).
    • Ampio has obtained the active ingredient, danazol, for the Optina clinical trial from CIPLA (Mumbai, India).
    • Ampio entered into a contractual agreement for the formulation of Optina™ with Green Mountain (Denver, Colorado) to produce the ultra-low doses of Optina™, which will be used in the forthcoming phase 2b clinical trials in the USA and elsewhere. The trials will be conducted under a 505(b)2 pathway in adherence to  guidance provided by the FDA at a pre-IND meeting and an IND application is being prepared.
    • Ampio will conduct pivotal trials in Europe (sites identified) for this indication.
    • Ampio was recently awarded multiple patents both in the USA and worldwide for Optina™.
    • Ampio is engaged in discussions with potential partners for Optina™.

    Sexual Dysfunction drugs

    This program includes Zertane™, for the treatment of premature ejaculation (PE), and Zertane ED™, for the treatment of com
    '/>"/>

    SOURCE Ampio Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Novation Champions Reusable Packaging for Sustainability in Healthcare
    2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
    3. Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
    4. Terso Solutions partners with Champion Medical Technologies to offer fully automated tracking of Tissue and Implantable Devices
    5. Champions Oncology to Present at Rodman & Renshaw Conference
    6. Champions Oncology Reports Resignation Of Director
    7. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
    8. Ampio Pharmaceuticals Announces Closing of Public Offering
    9. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
    10. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
    11. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... --  DocResponse was ranked the most accurate ... peer-reviewed study , "Evaluation of symptom checkers for ... the July issue of The British Medical Journal ... researchers determined that performance of online symptom checkers ... first in standardized patient evaluations more often than ...
    (Date:7/27/2015)... , July 27, 2015 VolitionRx ... focused on developing blood-based diagnostic tests for a broad ... that it has engaged the services of a specialty ... (GSS), to support initial U.S. market entry of its ... Under the agreement, GSS will target and select U.S. ...
    (Date:7/27/2015)... , July 27, 2015 Research and ... the "Intraoperative Imaging Market by Type (Intraoperative CT, ... Europe, Asia-Pacific, ROW) - Global Forecast to 2019" ... is expected to reach a value of $2.1 Billion ... CAGR of 3.5% during the forecast period. ...
    Breaking Medicine Technology:Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
    ... 30 Siemens Hearing Instruments, Inc., (www.usa.siemens.com/hearing) one of ... today announced several new product models and enhancements at ... of Audiology,s (ADA) 2009 Convention held October 29-31, 2009, ... the Motion, Explorer and Nitro lines support Siemens commitment ...
    ... Coulter, Inc. (NYSE: BEC ), a leading developer, ... innovate complex biomedical testing, announced today third quarter and ... third quarter revenue, including $65.1 million from the recent ... year quarter, or 11.6% in constant currency. On ...
    Cached Medicine Technology:Siemens Unveils New Hearing Loss Options at SPLASH: ADA's 2009 Convention 2Siemens Unveils New Hearing Loss Options at SPLASH: ADA's 2009 Convention 3Siemens Unveils New Hearing Loss Options at SPLASH: ADA's 2009 Convention 4Beckman Coulter Announces Third Quarter 2009 Results 2Beckman Coulter Announces Third Quarter 2009 Results 3Beckman Coulter Announces Third Quarter 2009 Results 4Beckman Coulter Announces Third Quarter 2009 Results 5Beckman Coulter Announces Third Quarter 2009 Results 6Beckman Coulter Announces Third Quarter 2009 Results 7Beckman Coulter Announces Third Quarter 2009 Results 8Beckman Coulter Announces Third Quarter 2009 Results 9Beckman Coulter Announces Third Quarter 2009 Results 10Beckman Coulter Announces Third Quarter 2009 Results 11Beckman Coulter Announces Third Quarter 2009 Results 12Beckman Coulter Announces Third Quarter 2009 Results 13Beckman Coulter Announces Third Quarter 2009 Results 14Beckman Coulter Announces Third Quarter 2009 Results 15Beckman Coulter Announces Third Quarter 2009 Results 16Beckman Coulter Announces Third Quarter 2009 Results 17Beckman Coulter Announces Third Quarter 2009 Results 18Beckman Coulter Announces Third Quarter 2009 Results 19Beckman Coulter Announces Third Quarter 2009 Results 20Beckman Coulter Announces Third Quarter 2009 Results 21Beckman Coulter Announces Third Quarter 2009 Results 22Beckman Coulter Announces Third Quarter 2009 Results 23Beckman Coulter Announces Third Quarter 2009 Results 24Beckman Coulter Announces Third Quarter 2009 Results 25Beckman Coulter Announces Third Quarter 2009 Results 26Beckman Coulter Announces Third Quarter 2009 Results 27Beckman Coulter Announces Third Quarter 2009 Results 28Beckman Coulter Announces Third Quarter 2009 Results 29Beckman Coulter Announces Third Quarter 2009 Results 30Beckman Coulter Announces Third Quarter 2009 Results 31Beckman Coulter Announces Third Quarter 2009 Results 32Beckman Coulter Announces Third Quarter 2009 Results 33
    (Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Eugene Batelli, ... an accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in ... months of Achilles tendon pain, which was diagnosed as tendinitis. I did an ...
    (Date:7/27/2015)... ... 27, 2015 , ... The Maricopa Community Colleges today announced a ... system to get into and complete college. , The “Bridging Success Initiative,” funded ... today with partners from across the valley. , The initiative advisory board has representatives ...
    (Date:7/27/2015)... ... July 27, 2015 , ... David Gilmour ... will be performing for one additional night at each of his original four tour ... for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, March ...
    (Date:7/27/2015)... (PRWEB) , ... July 27, ... ... on Global Calcium Propionate industry is a professional and in-depth research report. ... overview, industry chain structure, international market analysis etc. This report covers the ...
    (Date:7/27/2015)... Chico, CA (PRWEB) , ... July 27, 2015 , ... ... has teamed up with PursuitSAFETY to support its mission of reducing the number of ... funds to help support victims and their families. PursuitSAFETY works with the police ...
    Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
    ... Phase II for melanoma, to begin Phase II for breast ... cancer ... today at 9:00 a.m. EDT -, BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: ... the quarter ended March 31, 2008, CuraGen reported a net loss,of $6.8 million, or ...
    ... China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical,Group (NYSE: ... of,branded generic pharmaceuticals and manufacturer of the ... announced that it has,signed a definitive agreement ... Wuhu,Zhong Ren Pharmaceutical Co. Ltd. for a ...
    ... for the Service,Employees International Union claimed in an ... other acts of intimidation against,officers, directors and staff ... nothing more than "free speech.", A temporary ... Court Commission Jon Rantzman remains in effect today. ...
    ... treatment with drug 5-fluorouracil, study says , , MONDAY, April ... used chemotherapy drug causes memory problems and other cognitive ... brain," a new study found. , Up to 50 ... problems a year after chemotherapy treatment ended, according to ...
    ... DANVILLE, PA. Hearing repeated stories of suffering from ... workers, a new Geisinger-led study suggests. , In a ... Social Work Practice, Geisinger Senior Investigator Joseph Boscarino, PhD, ... and secondary trauma among 236 New York City social ...
    ... Appointed to Board ... of Directors, CINCINNATI, April 21, 2008 ... (Jack) F. Smith (70),will retire from the board following P&G,s April board meeting ... to:, http://www.prnewswire.com/mnr/pg/32757/ Mr. Smith has served on the board since 1995 ...
    Cached Medicine News:Health News:CuraGen Reports First Quarter 2008 Financial Results 2Health News:CuraGen Reports First Quarter 2008 Financial Results 3Health News:CuraGen Reports First Quarter 2008 Financial Results 4Health News:CuraGen Reports First Quarter 2008 Financial Results 5Health News:CuraGen Reports First Quarter 2008 Financial Results 6Health News:Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd. 2Health News:SEIU Claims Right of 'Free Speech' to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association 2Health News:Common Chemotherapy Drug Linked to Memory Problems 2Health News:Common Chemotherapy Drug Linked to Memory Problems 3Health News:Procter & Gamble Announces Board Changes 2
    The Shandon Cryotome E Cryostat model features an automated, precise electronic specimen advance system....
    The Shandon Pathcentre is a high-volume, totally enclosed tissue processor that allows complete user control and excellent continuous reagent agitation....
    ... Shandon Excelsior Tissue Processor is ... using traditional reagents today. It ... outstanding features to provide benefits ... increased productivity, reagent cost savings ...
    The Shandon Grosslab Grossing Workstation comes in a bench top or stand alone design for the gross examination and sectioning of specimens....
    Medicine Products: